In a mouse prostate cancer model, the deletion of Pml in Pten-null tumours resulted in the hyperactivation of SREBP and ultimately, in a SREBP-dependent aggressive metastatic phenotype (Chen et al., 2018). This evidence concerns the gene PML and neoplasm.